Download PDF
Thromb Haemost 1988; 60(03): 453-456
DOI: 10.1055/s-0038-1646989
Original Article
Schattauer GmbH Stuttgart

Modifications of Extrinsic Pathway Inhibitor (EPI) and Factor Xa that Affect their Ability to Interact and to Inhibit Factor Vila/Tissue Factor: Evidence for a Two-Step Model of Inhibition

Bonnie J Warn-Cramer
The Departments of Medicine and Pathology, University of California at San Diego, La Jolla, CA, USA
,
L Vijaya Mohan Rao
The Departments of Medicine and Pathology, University of California at San Diego, La Jolla, CA, USA
,
Steven L Maki
The Departments of Medicine and Pathology, University of California at San Diego, La Jolla, CA, USA
,
Samuel I Rapaport
The Departments of Medicine and Pathology, University of California at San Diego, La Jolla, CA, USA
› Author Affiliations
Further Information

Publication History

Received 20 May 1988

Accepted after revision 28 July 1988

Publication Date:
30 June 2018 (online)

Also available at
  PDF Download Permissions and Reprints

Summary

Inhibition of factor VIIa/tissue factor (TF) by extrinsic pathway inhibitor (EPI) requires the participation of factor Xa. Through this inhibition, factor Xa generated initially may feed back to suppress continuing generation of factor Xa via the extrinsic pathway during hemostasis. We have utilized chemical modifications of EPI and factor Xa to study the reactions responsible for inhibition. The data are consistent with a two-step model. First, EPI binds to factor Xa in a Ca2+ independent reaction in which the gla-domain of factor Xa does not participate. A functional active site on factor Xa and arginine residues on EPI are essential for this step. Then the factor Xa/EPI complex binds to factor VIIa/TF with resultant inhibition of its enzymatic activity. The gla-domain of factor Xa is essential for this step. Intact positively charged lysines on factor Xa may also be important

Keywords

Extrinsic pathway inhibitor - Tissue factor - Factor VIIa - Factor Xa - Γ-Carboxyglutamic acid
 

  • References

  • 1 Sanders NL, Bajaj SP, Zivelin A, Rapaport SI. Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. Blood 1985; 66: 204-212
    PubMedGoogle Scholar
  • 2 Rao LV M, Rapaport SI. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood 1987; 69: 645-651
    PubMedGoogle Scholar
  • 3 Broze Jr GJ, Miletich JP. Characterization of the inhibition of tissue factor in serum. Blood 1987; 69: 150-155
    PubMedGoogle Scholar
  • 4 Broze Jr GJ, Miletich JP. Isolation of the tissue factor inhibitor produced by HepG2 hepatoma cells. Proc Natl Acad Sci USA 1987; 84: 1886-1890
    CrossrefPubMedGoogle Scholar
  • 5 Broze Jr GJ, Warren LA, Novotony WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VH-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action. Blood 1988; 71: 335-343
    PubMedGoogle Scholar
  • 6 Warn-Cramer BJ, Rao LV M, Maki SL, Rapaport SI. Both the gla domain of F. Xa and its active site participate in the F. Xa-dependent inhibition of F. VIIa/tissue factor activity.. Blood 1987; 70 (Suppl. 01) 1441
    PubMedGoogle Scholar
  • 7 Rao LV M, Bajaj SP. Purification of human factor VII utilizing O-(diethylaminoethyl)-Sephadex and Sulfopropyl Sephadex chromatography. Anal Biochem 1984; 136: 357-361
    CrossrefPubMedGoogle Scholar
  • 8 Bajaj SP, Rapaport SI, Prodanos C. A simplified procedure for purification of human prothrombin, factor IX and factor X. Prep Biochem 1981; 11: 397-412
    PubMedGoogle Scholar
  • 9 Usharani P, Warn-Cramer BJ, Kasper CK, Bajaj SP. Characterization of three abnormal factor IX variants (Bm Lake Elsinore, Long Beach, and Los Angeles) of hemophilia-B. J Clin Invest 1985; 75: 76-83
    CrossrefPubMedGoogle Scholar
  • 10 Rao LV M, Rapaport SI. Affinity purification of human brain tissue factor utilizing factor VII bound to immobilized anti-factor VII. Anal Biochem 1987; 165: 365-370
    CrossrefPubMedGoogle Scholar
  • 11 Warn-Cramer BJ, Maki SL, Zivelin A, Rapaport SI. Partial purification and characterization of extrinsic pathway inhibitor (The factor Xa-dependent plasma inhibitor of factor Vila/tissue factor). Thromb Res 1987; 48: 11-22
    CrossrefPubMedGoogle Scholar
  • 12 Morita T, Jackson CM. Preparation and properties of derivatives of bovine factor X and factor Xa from which the Γ-carboxyglutamic acid containing domain has been removed. J Biol Chem 1986; 261: 4015-4023
    PubMedGoogle Scholar
  • 13 Mahley RW, Innerarity TL, Pitas RE, Weisgraber KH, Brown JH, Gross E. Inhibition of lipoprotein binding to cell surface receptors of fibroblasts following selective modification of arginyl residues in arginine-rich and B apoproteins. J Biol Chem 1977; 252: 7279-7287
    PubMedGoogle Scholar
  • 14 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
    CrossrefPubMedGoogle Scholar
  • 15 Rao LV M, Rapaport SI, Bajaj SP. Activation of human factor VII in the initiation of tissue factor-dependent coagulation. Blood 1986; 68: 685-691
    PubMedGoogle Scholar
  • 16 Laskowski Jr. M, Kato I. Protein inhibitors of proteinases. Annu Rev Biochem 1980; 49: 593-626
    CrossrefPubMedGoogle Scholar
  • 17 Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze Jr GJ. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988; 263: 6001-6004
    PubMedGoogle Scholar
  • 18 Rao LV M, Rapaport SI, Bajaj SP. Activation of human factor VII in the initiation of tissue factor dependent coagulation. Blood 1986; 68: 685-691
    PubMedGoogle Scholar